Wayne Kuznar


Parsaclisib Elicits Encouraging Response Rates in Relapsed/Refractory Follicular Lymphoma

December 17th 2021

Parsaclisib, an investigational highly selective phosphatidylinositol 3-kinase δ inhibitor, demonstrated rapid and durable responses as monotherapy with an acceptable safety profile in patients with relapsed/refractory follicular lymphoma in the phase 2 CITADEL-203 study.

Red Blood Cells Stored in Hypoxic State Show Lower Adhesion Levels Vs Normoxia

December 17th 2021

Red blood cells processed and stored in a hypoxic state maintain their integrity, which may reduce the risk of developing vaso-occlusion after red blood cell transfusion.

High-Frequency Low-Dose Acalabrutinib/Rituximab Combo Elicits 100% ORR in Frontline CLL/SLL

December 14th 2021

High-frequency low-dose acalabrutinib and rituximab represents a feasible and effective combination for the treatment of patients with previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma.

Glofitamab Monotherapy, Plus Obinutuzumab Show High Responses in Relapsed/Refractory Follicular Lymphoma

December 13th 2021

Glofitamab, an investigational CD20xCD3 bispecific antibody, induced high response rates as monotherapy or in combination with obinutuzumab in patients with multiple relapsed or refractory follicular lymphoma.

Strong Antibody Response to mRNA COVID-19 Vaccine Observed in AML, MDS

December 11th 2021

An observational single-center study suggests that mRNA-1273 SARS CoV-2 vaccination induces a strong antibody response in patients with acute myeloid leukemia and myelodysplastic syndrome, according to observational results presented during the 2021 ASH Annual Meeting.

Acalabrutinib, Alone or With Obinutuzumab, Improves Quality-Adjusted Survival in Frontline CLL

September 22nd 2021

Treatment with acalabrutinib as monotherapy or in combination with obinutuzumab improved quality-adjusted survival compared with chlorambucil plus obinutuzumab in patients with treatment-naïve chronic lymphocytic leukemia.

Blood-Based TMB Is Not Predictive of Benefit With Atezolizumab in NSCLC

September 21st 2021

Blood-based tumor mutational burden does not predict a benefit of first-line atezolizumab over chemotherapy in patients with non–small cell lung cancer.

Zanubrutinib Responses Deepen Over Time in Relapsed/Refractory CLL

September 20th 2021

Zanubrutinib monotherapy showed a deepening of response in patients with relapsed/refractory chronic lymphocytic leukemia.

Splicing Molecule Delays Leukemic Infiltration in CLL, Has Targeted Therapy Potential

September 17th 2021

H3B-8800, a splicing molecule that binds to Splicing Factor 3b Subunit 1, has been shown to delay leukemic infiltration in a model of chronic lymphocytic leukemia using NOD-SCID interleukin-2 receptor gamma mice.

Olaparib Rechallenge Improves PFS in Relapsed Ovarian Cancer Previously Treated With PARP Inhibition

September 17th 2021

Rechallenge with maintenance olaparib following response to platinum-based chemotherapy significantly improved progression-free survival in heavily pretreated patients with relapsed ovarian cancer, irrespective of BRCA status, according to results of the phase 3 OReO/ENGOT Ov-38 study.

Mobocertinib Shows Improved Responses Vs Real-World Data in Advanced EGFR Exon 20 Insertion+ NSCLC

September 16th 2021

Mobocertinib, a novel EGFR tyrosine kinase inhibitor, exhibited clinically meaningful activity in patients with non–small cell lung cancer who harbor EGFR exon 20 insertion mutations following frontline platinum-based chemotherapy when compared indirectly with real-world data of patients treated with standard of care.

Linagliptin/Atezolizumab Combo Shows Limited Clinical Activity in Second-Line Gastric/GEJ Cancer

September 16th 2021

Linagliptin plus atezolizumab was linked with limited responses as a second-line treatment for patients with locally advanced or metastatic gastric or gastroesophageal junction cancer who participated in an arm of the open-label, phase 1b/2 MORPHEUS platform.

Third-Line CAR T-Cell Therapy Improves Outcomes in B-Cell Lymphomas

April 1st 2021

CAR T-cell therapies are now incorporated into National Comprehensive Cancer Network guidelines as a recommended third-line strategy in this setting, with the most recent addition being lisocabtagene maraleucel.

Checkpoint Inhibition Makes Way Into NCCN Urothelial Cancer Guidelines in Maintenance and Second-Line Setting

March 20th 2021

Immunotherapy is now incorporated into National Comprehensive Cancer Network guidelines as maintenance therapy and in a sequencing strategy for the treatment of patients with metastatic urothelial carcinoma and in the setting of superficial UC-carcinoma in situ with prior intravesical therapy.

Itolizumab Leads to Sustained Clinical Responses in Newly Diagnosed Acute GVHD

February 16th 2021

February 16, 2021 - Itolizumab, a humanized IgG1 monoclonal antibody that modulates the activated leukocyte cell adhesion molecule pathway, represents a promising approach for the treatment of patients with newly diagnosed acute graft-versus-host disease.

Beti-Cel Gene Therapy Frees Patients With Beta-Thalassemia From Red Blood Cell Transfusions

February 15th 2021

February 15, 2021 - Betibeglogene autotemcel, a one-time gene therapy, enabled durable transfusion independence in most patients with transfusion-dependent β-thalassemia who were treated across 4 clinical studies.

Response to Prior Therapy Predicts Outcomes With Axi-Cel in Refractory Large B-Cell Lymphoma

February 9th 2021

February 9, 2021 - Patients with refractory large B-cell lymphoma have less to gain from axicabtagene ciloleucel if they have never achieved a complete response to any line of prior therapy.

Imetelstat Has Disease-Modifying Activity in Relapsed/Refractory Myelofibrosis, as Shown by Effect on Telomerase Activity

January 19th 2021

January 19, 2021 - Imetelstat exhibited dose-dependent inhibition of the telomerase target, as evaluated by reductions in telomerase activity, human reverse transcriptase levels, and telomere length, in patients with relapsed/refractory myelofibrosis who were enrolled in the phase 2 IMbark trial.

Tamoxifen Reduces Mutation Allele Burden in MPN Subset Identified Via RNA Sequencing

January 18th 2021

January 18, 2021 - The phase 2 TAMARIN study exploring the activity of tamoxifen on driver variant allele frequency in patients with stable myeloproliferative neoplasms met its primary end point.

More Than 2 Cycles of Cisplatin Significantly Reduces Risk of Second Testicular Cancer

January 15th 2021

January 15, 2021 - The risk of a second metachronous contralateral germ cell testicular cancer is found to be significantly reduced with each additional cycle of cisplatin-based chemotherapy in patients.